Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ...

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

Merck (MRK) stock gains as its bestselling drug, Keytruda, as part of a combination regimen, succeeds in a Phase 3 trial for ...

Jefferies analyst Akash Tewari notes that new Medicare Part B & D draft guidance has been released and that Merck (MRK) and Bristol Myers (BMY) are trading down due to updated language on single ...

Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...

US pharma giant Merck & Co (NYSE: MRK) today announced that the Phase III KEYNOTE-B96 trial, also known as ENGOT-ov65, met ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Find insight on Merck and Exelixis in the latest Market Talks covering Health Care.

We recently published a list of 13 Best Cheap Stocks to Invest in for Beginners. In this article, we are going to take a look ...

BioNTech's BNT324 aims to outpace rivals in cancer treatment with its unique bispecific antibody design. Read more here.

American depository receipts of Immutep rose after the company reported positive results from a trial of its combination treatment for non-small cell lung cancer. Immutep climbed 16% to $2.11 on ...

We recently published a list of the 20 Best Dividend Growth Stocks with High Yields. In this article, we are going to take a ...